8 June 2018 - PHARMAC is pleased to announce a decision to fund denosumab (Prolia) for the treatment of severe, established osteoporosis, subject to certain clinical criteria being met.

This decision relates to a proposal detailed in a consultation letter dated 16 March 2018. 

The final criteria are wider than those consulted on in that the restriction by gender has been removed.

Read PHARMAC notification